Strides Pharma Science Ltd has reported a consolidated net loss of Rs 163.4 crore in the first quarter ended in June 2022, compensated by higher revenue. The company reported a consolidated net loss of Rs 244.1 crore for the same quarter a year ago. Revenue from operations stood at Rs 940.07 crore compared to Rs 688.37 crore in the year-ago period, marking a growth of 36.6 per cent.

• Tata Motors Announced Tie-up with South Indian Bank
• Waaree Energies Received a Supply Order for 400 MW Modules 
• Techno Electric Shares Hit 52-Week High on Securing Orders Worth Rs 4,000 Crore
• IREDA Shares Skyrocketed 11% on Receiving Navratna Status 
• Glenmark Pharma Shares Gain 1% on Receiving USFDA Approval 

The company reported that its revenues from Other Regulated Markets (ORM) were at Rs 304.7 crore in the first quarter of FY23, compared to Rs 223.2 crore in the corresponding fiscal period. Higher costs remain a cause of concern, and the company is focused on cost controls and manufacturing network optimization.